Search

Displaying results 4671 - 4680 of 10000 in total
  1. Drug

    Brilaroxazine

    go.drugbank.com/drugs/DB09226
    Investigational

    As of May 2015, it is in phase III clinical trials for schizophrenia. … Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder.

  2. Drug

    Neratinib

    go.drugbank.com/drugs/DB11828
    ApprovedInvestigational

    Neratinib is currently under investigation for use in many other forms of cancer.

    Products: NERLYNX FILM-COATED TABLETS 40 MG, NERLYNX (neratinib) Film-Coated Tablets 40 mg
  3. Drug

    Human papillomavirus type 6 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10299
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces

  4. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

  5. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. … It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections

  6. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    It is used in the management of myasthenia gravis.

  7. Drug

    GFT14

    go.drugbank.com/drugs/DB05061
    Experimental

    GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. … ) and on other risk factors such as hypertension or diabetes.

  8. Drug

    REP8839

    go.drugbank.com/drugs/DB05224
    Experimental

    REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

  9. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.

    Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYETTA 5 µG/20 µL SC KULLANIMA HAZIR DOLU ENJEKSİYON KALEMI ICINDE COZELTI, 1.2 ML (60 DOZ)
  10. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.